oral semaglutide vs oral tirzepatide versus Once Weekly in Patients with Type 2 Diabetes oral.tirzepatide MangoRx to Introduce Oral

Further investigations by Ng et al

While it is still not FDA-approved, it is being clinically tested and studied as a solution for obesity

This directly addresses the increased appetite and carbohydrate cravings commonly reported during hormonal transitions

In the UK, the regulatory pathway for new medicines requires submission of a Marketing Authorisation Application (MAA) to the MHRA

The SUMMIT trial took this further with tirzepatide, showing a 38% reduction in the composite of cardiovascular death or worsening heart failure (HR 0.62) in patients with HFpEF and obesity, along with a clinically meaningful 6.9-point improvement in KCCQ scores

Demonstrates anti-inflammatory and cytoprotective properties in preclinical settings [6]